123 related articles for article (PubMed ID: 2652343)
1. [Plasma cell leukemia. Study of 10 cases].
López Guillermo A; Martí JM; Bladé J; Nomdedeu B; Montserrat E; Rozman C
Sangre (Barc); 1989 Feb; 34(1):28-31. PubMed ID: 2652343
[TBL] [Abstract][Full Text] [Related]
2. [Plasma cell leukemia. Study of 6 patients].
Las Heras G; Ribera JM; Abella E; Batlle M; Flores A; Millá F; Feliu E
Sangre (Barc); 1992 Aug; 37(4):255-8. PubMed ID: 1514138
[TBL] [Abstract][Full Text] [Related]
3. [Plasma cell leukemia: our experience in 4 cases].
Manso F; Bello JL; Feliu J; García de Bustos J; Losada G; Quevedo E
Rev Clin Esp; 1991 Nov; 189(7):328-30. PubMed ID: 1767090
[TBL] [Abstract][Full Text] [Related]
4. Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia.
Cha CH; Park CJ; Huh JR; Chi HS; Suh CW; Kang YK
Acta Haematol; 2007; 118(3):178-82. PubMed ID: 17934254
[TBL] [Abstract][Full Text] [Related]
5. [Clinical and evolutive study of plasma cell leukemia. Apropos of 9 cases].
Panizo Santos C; Cuesta Palomero B; Calasanz Abinzano MJ; Rifón Roca J; Rocha Hernando E
Rev Clin Esp; 1997 May; 197(5):341-5. PubMed ID: 9280968
[TBL] [Abstract][Full Text] [Related]
6. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia.
Vela-Ojeda J; García-Ruiz Esparza MA; Rosas-Cabral A; Padilla-González Y; García-Chávez J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; García-León LD; Montiel-Cervantes L; Rubio-Borja ME
Ann Hematol; 2002 Jul; 81(7):362-7. PubMed ID: 12185504
[TBL] [Abstract][Full Text] [Related]
7. A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China.
Peijing Q; Yan X; Yafei W; Dehui Z; Zengjun L; Junyuan Q; Yaozhong Z; Lugui Q
Acta Haematol; 2009; 121(1):47-51. PubMed ID: 19339770
[TBL] [Abstract][Full Text] [Related]
8. Plasma cell leukemia. A report on 11 patients and review of the literature.
Pasqualetti P; Festuccia V; Collacciani A; Acitelli P; Casale R
Panminerva Med; 1996 Sep; 38(3):179-84. PubMed ID: 9009684
[TBL] [Abstract][Full Text] [Related]
9. Primary systemic amyloidosis with delayed progression to multiple myeloma.
Rajkumar SV; Gertz MA; Kyle RA
Cancer; 1998 Apr; 82(8):1501-5. PubMed ID: 9554527
[TBL] [Abstract][Full Text] [Related]
10. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of bortezomib in patients with plasma cell leukemia.
Musto P; Rossini F; Gay F; Pitini V; Guglielmelli T; D'Arena G; Ferrara F; Filardi N; Guariglia R; Palumbo A; ; ;
Cancer; 2007 Jun; 109(11):2285-90. PubMed ID: 17469169
[TBL] [Abstract][Full Text] [Related]
12. Plasma cell leukemia.
Kosmo MA; Gale RP
Semin Hematol; 1987 Jul; 24(3):202-8. PubMed ID: 3116673
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
[TBL] [Abstract][Full Text] [Related]
14. Plasma cell leukemia: a rare condition.
Jiménez-Zepeda VH; Domínguez VJ
Ann Hematol; 2006 Apr; 85(4):263-7. PubMed ID: 16416115
[TBL] [Abstract][Full Text] [Related]
15. Plasma cell leukemia: response to conventional myeloma therapy.
Gailani S; Seon BK; Henderson ES
J Med; 1977; 8(6):403-14. PubMed ID: 272434
[TBL] [Abstract][Full Text] [Related]
16. [Primary plasma cell leukemia--a comprehensive analysis of 44 cases].
Cai ZJ
Zhonghua Zhong Liu Za Zhi; 1990 Jul; 12(4):314-7. PubMed ID: 2272272
[TBL] [Abstract][Full Text] [Related]
17. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
[TBL] [Abstract][Full Text] [Related]
19. [Non-secretory primary plasma cell leukemia with hyperammonemia].
Kawano F; Tsukamoto A; Satoh M; Sanada I; Shido T; Miura K; Murakami T; Kaneko H; Takeya M; Matsuzaki H
Rinsho Ketsueki; 1991 Apr; 32(4):399-403. PubMed ID: 2067085
[TBL] [Abstract][Full Text] [Related]
20. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
